Q32 Bio Reports Q3 Results, Initiates Registration-Directed Program in 1H27
Q32 Bio reported solid cash and results for the third quarter, noting that revenue is not material. The company expects to initiate a registration-directed program for bempikibart in severe alopecia areata in the first half of 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed